|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
Autoantibodies and Pregnancy in Rheumatic Diseases
a Rheumatology and Clinical Immunology, Brescia Hospital and University, Brescia, Italy b Neonatal Intensive Care Unit, Brescia Hospital, Brescia, Italy c Obstetrics and Gynecology Department, Brescia Hospital and University, Brescia, Italy
Key Words: rheumatic disease • pregnancy • antiphospholipid antibodies • anti-Ro/SS-A antibodies • neonatal lupus • corticosteroids • intravenous immunoglobulin • antiplatelet antibodies
Address for correspondence: Dr. A. Tincani, Rheumatology and Clinical Immunology, Ospedale Civile, Piazzale Spedali Civili no. 1, 25123 Brescia, Italy. Voice: 030-399-5488; fax: 030-399-5085. e-mail: tincani{at}bresciareumatologia.it
In women who suffer from rheumatic diseases (RDs) the risk of repeated fetal loss, intrauterine growth restriction, and preterm birth remains higher than in the general population. Antiphospholipid antibodies are frequently observed in patients with systemic lupus erythematosus (SLE). They are associated with recurrent pregnancy losses that may occur at any age of gestation. The cause of fetal death is believed to be intraplacental thrombosis, although other pathologic mechanisms have been described. A recent study has described the increased frequency of learning disabilities in the offspring of SLE patients; case reports of neonatal thrombosis are very rare. Transplacental passage of IgG anti-Ro/SS-A antibodies is linked to neonatal lupus (2%). The main manifestation is congenital heart block (CHB) due to the binding of anti-Ro/SS-A antibodies to cardiac conduction tissue and to the consequent inflammatory/fibroid reaction. Neonatal lupus also includes cutaneous, hematologic, and hepatobiliary manifestations, which are typically transient. Incomplete CHB can be treated with fluorinated corticosteroids to prevent the progression and decrease inflammation. Intravenous immunoglobulin, decreasing the tranplacental passage of anti-Ro/SS-A, has been proposed as prophylactic therapy in patients who had one or more child with CHB. Transplacental passage of antiplatelet antibodies, in about 10% of mothers with SLE, can induce thrombocytopenia in the fetus or the neonate. Patients with RD have a higher incidence of anxiety and depression compared to the general population, interfering with parenthood and the upbringing of children.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||
 |
 |
